Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Lexogen presenta CORALL RNA-Seq V2

  • USA - Français
  • USA - English
  • USA - Deutsch
(PRNewsFoto/Lexogen)

News provided by

Lexogen

Apr 27, 2022, 11:18 ET

Share this article

Share toX

Share this article

Share toX

-  Lexogen presenta CORALL RNA-Seq V2: un kit de preparación de bibliotecas de RNA-Seq de transcriptoma completo rápido y flexible

Obtenga los mejores resultados de secuenciación para todos los tipos y calidades de muestras

VIENA, 27 de abril de 2022 /PRNewswire/ -- Lexogen, una compañía de transcriptómica y secuenciación de próxima generación, anunció hoy el lanzamiento del nuevo kit de preparación de bibliotecas de transcriptomas completos, CORALL RNA-Seq V2.

El análisis de transcriptoma completo con secuenciación de ARN (RNA-Seq) está a la vanguardia de las capacidades de NGS y permite determinar las moléculas de ARN en una muestra en el momento del muestreo. El transcriptoma es una característica celular altamente dinámica y RNA-Seq abre un mundo de potencial de descubrimiento. Entre las aplicaciones más comunes de RNA-Seq se encuentran los estudios de expresión génica, por ejemplo, cambios transcripcionales en respuesta al tratamiento farmacológico o durante varios estados de desarrollo, así como estudios de corte y empalme alternativos y análisis de isoformas de transcripción en diferentes tejidos o en salud y enfermedad.

CORALL RNA-Seq V2 se basa en las tecnologías patentadas presentadas anteriormente de desplazamiento/parada y ligadura. Es un kit rápido y flexible para la secuenciación de transcriptomas completos con un amplio rango de entrada y un rendimiento excepcional incluso para entradas bajas (hasta 1 ng de ARN total) y muestras comprometidas. A diferencia de WTS RNA-Seq convencional, la preparación de la biblioteca CORALL requiere solo 6 pasos y puede completarse en 4,5 horas. CORALL no requiere la fragmentación del ARN y, por lo tanto, es perfectamente adecuado para el procesamiento de material FFPE o ARN altamente degradado.

CORALL RNA-Seq V2 añade varias mejoras a la tecnología bien establecida, mejorando el rendimiento y la robustez del kit e introduciendo la posibilidad de ajustar el tamaño de la biblioteca sin usar la fragmentación del ARN. Esta nueva característica hace que CORALL RNA-Seq V2 sea ideal para aplicaciones desafiantes de RNA-Seq, como la detección de isoformas, la (re) anotación de transcripciones o el estudio de transcripciones de fusión. El kit está disponible de forma independiente, como paquete mRNA-Seq que incluye selección de poli(A) y como paquete Total RNA-Seq que incluye agotamiento de ARNr de RiboCop para un rendimiento de la más alta calidad.

"Podemos apoyar muy bien a nuestros investigadores utilizando la preparación de la biblioteca CORALL RNA-Seq de Lexogen", explicó la doctora Pamela Nicholson, responsable de la Plataforma de Secuenciación de Próxima Generación en la Universidad de Berna en Suiza. "Encontramos que el protocolo es sencillo y podemos generar bibliotecas muy consistentes perfectas para proyectos estándar de RNA-Seq. Gracias a CORALL RNA-Seq V2 ahora tenemos la opción de generar bibliotecas con tamaños de inserción más largos [...]. Esto es muy útil, por ejemplo, para RNA-Seq para organismos no modelo, para mapeo mejorado para proyectos exigentes y para proyectos que caracterizan isoformas".

Aprenda más acerca de los beneficios del kit de preparación de bibliotecas CORALL RNA-Seq V2. 

Acerca de Lexogen

Establecida en el año 2007, Lexogen es una empresa líder en transcriptómica, secuenciación de próxima generación y análisis de ARN. La misión del equipo de Lexogen es empoderar a sus clientes con soluciones innovadoras de análisis de ARN y soporte de alta calidad, para mejorar la salud y el bienestar de todos y de nuestro planeta. Lexogen es el líder en secuenciación de ARN 3', una tecnología probada por su eficacia, robustez y sensibilidad. La cartera de Lexogen incluye kits innovadores para la secuenciación de ARN unicelular real y a granel, la purificación de ARN y el agotamiento del ARN ribosómico, los controles de variantes de ARN adicionales y el etiquetado de ARN metabólico. Lexogen también proporciona servicios de análisis de ARN totalmente integrados y de primera clase, desde el diseño experimental hasta la generación de informes analíticos.

Lexogen es una compañía de propiedad privada con sede sita en Viena, Austria, y con una filial en New Hampshire, Estados Unidos.

Si desea conocer más visite www.lexogen.com y siga a @lexogen.

Persona de contacto:
Amra Dedic
Responsable de comunicaciones y eventos
Teléfono: +43 660 69 66 045
E-mail: [email protected]

Logo - https://mma.prnewswire.com/media/472869/Lexogen_logo_Logo.jpg

21%

more press release views with 
Request a Demo

Modal title

Also from this source

Lexogen Featured in Labiotech's Beyond Biotech Podcast on AI-Driven Drug Discovery

Lexogen Featured in Labiotech's Beyond Biotech Podcast on AI-Driven Drug Discovery

A new episode of Beyond Biotech podcast, produced by Labiotech, is now live, featuring Dr. Stéphane Barges, CEO of Lexogen, alongside Dr. Quin Wills, ...

Lexogen Featured in Labiotech's Beyond Biotech Podcast on AI-Driven Drug Discovery

Lexogen Featured in Labiotech's Beyond Biotech Podcast on AI-Driven Drug Discovery

A new episode of Beyond Biotech podcast, produced by Labiotech, is now live, featuring Dr. Stéphane Barges, CEO of Lexogen, alongside Dr. Quin Wills, ...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

Medical Equipment

Medical Equipment

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2026 Cision US Inc.